clastoban800 ml
torna all'INDICE farmaci


Google  CERCA FARMACI NEL SITO

  www.carloanibaldi.com

01.0 DENOMINAZIONE DEL MEDICINALE
02.0 COMPOSIZIONE QUALITATIVA E QUANTITATIVA
03.0 FORMA FARMACEUTICA
04.0 INFORMAZIONI CLINICHE
04.1 Indicazioni terapeutiche
04.2 Posologia e modo di somministrazione
04.3 Controindicazioni
04.4 Speciali avvertenze e precauzioni per l'uso
04.5 Interazioni
04.6 Gravidanza e allattamento
04.7 Effetti sulla capacitÓ di guidare veicoli e sull'uso di macchine
04.8 Effetti indesiderati
04.9 Sovradosaggio
05.0 PROPRIETA' FARMACOLOGICHE
05.1 ProprietÓ farmacodinamiche
05.2 ProprietÓ farmacocinetiche
05.3 Dati preclinici di sicurezza
06.0 INFORMAZIONI FARMACEUTICHE
06.1 Eccipienti
06.2 IncompatibilitÓ
06.3 Periodo di validitÓ
06.4 Speciali precauzioni per la conservazione
06.5 Natura e contenuto della confezione
06.6 Istruzioni per l'uso e la manipolazione
07.0 TITOLARE DELL'AUTORIZZAZIONE ALL'IMMISSIONE IN COMMERCIO
08.0 NUMERI DELLE AUTORIZZAZIONI ALL'IMMISSIONE IN COMMERCIO
09.0 DATA DELLA PRIMA AUTORIZZAZIONE/RINNOVO DELL'AUTORIZZAZIONE
10.0 DATA DI REVISIONE DEL TESTO

01.0 DENOMINAZIONE DEL MEDICINALE -[Vedi Indice].

02.0 COMPOSIZIONE QUALITATIVA E QUANTITATIVA - [Vedi Indice].

03.0 FORMA FARMACEUTICA - [Vedi Indice].

04.0 INFORMAZIONI CLINICHE - [Vedi Indice].

04.1 Indicazioni terapeutiche - [Vedi Indice].

04.2 Posologia e modo di somministrazione - [Vedi Indice].

04.3 Controindicazioni - [Vedi Indice].

04.4 Speciali avvertenze e precauzioni per l'uso - [Vedi Indice].

04.5 Interazioni - [Vedi Indice].

04.6 Gravidanza e allattamento - [Vedi Indice].

04.7 Effetti sulla capacitÓ di guidare veicoli e sull'uso di macchine - [Vedi Indice].

04.8 Effetti indesiderati - [Vedi Indice].

04.9 Sovradosaggio - [Vedi Indice].

05.0 PROPRIETA' FARMACOLOGICHE - [Vedi Indice].

05.1 ProprietÓ farmacodinamiche - [Vedi Indice].

05.2 ProprietÓ farmacocinetiche - [Vedi Indice].

-1.3 %쏢 5 0 obj <> stream x]nEW.@gv$dr @ER dR zsOMPT W׻=Y׫<+U>~:W8x}efkO^~{tٷ�Z=?ȳ+ӌߋU٘.WmeoMT__7tUխʋW*80EjS4Y::~;&Rvyޯ|hk/Oc쯲:] fb_Ra0>K$0:e5Kf[-jSPP^maL]VmcnmB-ʼmaRa>eS,$T(KOBmu첶ȶ8(fux_ 3|{|p뿭q&}oZgn8MQ7M6am?&;K̮GᦴqeV>yu4tTU'iTyYD_SjnD[l#=$So ltƸ솚&l°IrK*2̟m)sˀX7u[ڕϿ ߌΝ[g'V~uXgzzȳm|Ǻ'ޞb^Zhڦ^_KᛁH K-|ٶ]чu~/]┘Ը''[FuhBͦk`gMq)WcEfx ?7Đ;"/62< O ?&}Eb^`Lټ tQuM@0 +ͧ᧹7MT[YEKzzik{Vm-~/; $Z*)h O6Sv9j:+eG= BW=~yceSܪ[w͏uv@mͧb (pg# t <.(WgE.;pQKo#^fkt-L64^pgxR5f`ShZԘ,GQ׍P#Jhp]?ݮRصFbgkW$ I\tLԏȆ.I)VX9EU .wmັ3{+xf DI|VRz- asai!#G㳓, }|譛3Q< \FPa§Y/%)&*R u[V XUSb.9UN*Y=`+W[DA4aA5qq] j갬Q&c vY0zTιy2- ) TO\Y AULJ9#8,M]dw(`.H_C#.݄ Wi"㌼ip˨X_ @3AihMu~3Mm t.rTG^Ǫ@^qo"/([/|[oF*rfƗqm]W~h<܀3.>[>R]{W1G ^蘻5L//AF VD?D,?ZOE}$Rk\4Mh]0>Yn^8+qYLLde݅oxRHKiu1e7(ΖUt&Q+e>B{ȑqޣҨrq7u&FKG1G1' R&"b@sC8F`Ǥ*K2&mLJ?\BkSrĘ\,ƞJLhゟȾ CSYٞ;&ĸ78 & UKXUU <9(Vu){[uUX:XU7gw&]L }Sޮ٠'@+qi439$&I2"8`I 4Y|< F|Ġ;]b?;`Zsj!jOI )7+!E*97z]Kh#w;XX94y e?J'2T3g|м t H-ltN <6,3Azlf!m;]uըF]߉(FUmC DC§G91/a%`ܲZ䅥Zcw&N~tb#U7VejKb,1I<)wȚ&Eɀ>M̍fMF*moEa}Z?!kaL9鄡g?+evo^AHGJy$\ckW0NK\s˽]ޖL"b[aCZ9!#L@hłv[~224:O$)rVDs;I K"fm/ĭ&DZ咊%bag׽OXy[:Qiub_d jId^ }C|NQG %qƈՕf ]k y ĕHرfϱkPRW#>c3UsxlƟ+6 |WVР-Cj:`RFC 7F0-8mm]Q.3!2CjKGcso&#dBep۴ם&LwcgD528]т4݄]t`rxj6kz9ՎT9 r# ,=Cqm%p8I\AM"M ]OLw__.q5͝M 'l̄=-V}XG&y4"xu\ϗ"d2VY|RD kdt+*WVdK´9b<<TR\uX൓Ӂpe-vLI[4P]vs1GXxj̺\" vdNʼnr')qPEp*+ Eá/<:/SPκUe GSuַ5H nY-ɥY,~tv֋QG[!][*P4o0Lx[Lc䪭׋s;c:^y!7ggvNILIbW ő׊*k(pIOJ.?'B%3WqZ\y2bB l'^탽',"$p'Ax^)-oi?Ѕ+o ۛҺpYn*dt]\22& Y~o(;4э DH=pw}A1V/r$fV NSi9Tq'~-+v+ #%"%*an?|o (0UvJ*Ah|CwJG;nbn٬`UJ貼Ȼ{}ZNS"kg8t=f=DГXc?Spq<Ɵ.UyMw甼$^ȘޱߔjS aTS/ {Juۂ_=J` ^b V&2gq2ɞd˝+ƥttY/WxWfxI|P62Е,;_gO endstream endobj 6 0 obj 5263 endobj 15 0 obj <> stream x]r$Gr+63&Q9N K/ch4Du HPdfDUH5?lvEYmvӿwg͟> E="3"_eܔek6v8nb]YTwg PVm.?ŮƱm1]6ceW.]m*?O3noMb,Dz4MMoNݮj\ieQW4 ]W2W۽(w#:>Kk3ѱ~(G3yz{'w;ЭizlA/S?>z50U`f ="4"Mnn07 TQi0^Y ES.o~r35~WU#vM<_z7=lڡa!wfһqF,3vMc&8-É|M^,PYmNe_)ahF|odnW ~`90ю^j9~cc]o:0`Os](< W/dhƲYP,cB՚"kF_~fa4rNC?3{XnL-dOncDDg//TͮMrVG^4 4D=ܪ̯WQFD6u\e_Zv[2^#dJ O ǰ{<@$ Fݜ`B( q/<R\TэRԠƨ[/)M/Hp=VGgHlsBdp}Ɛ[_m0\/i1t翯C.iRY>Jt;mJB`eBK7 `wo -nfcos um3 D"'--b=D7WEb:Q4<pl@*|)bWS_5 kTpε"cLԻ@ga{$K*[ %8*_ %mVB[I*K}/S3-ӊbm3|/&5ctx^3NM(R 7D]i)׋>P~ &ƄDƸ(7x#O?y}rDA$6'oz˴sʷ26]x^a8 7>}uP fF,ۭFWb, %ٶW$aCl1=7KǦֆD*lm7zA{ huX}'XhLAcL,>y):P"%HdqJ0S'f^+{S!\zitֽ%^ *u\u└Ѝ`PteD_v9=*~<7k%\Imm?D[a]7ދ4b!%B -155@q/T˨i ؀P|pt%bчtD_* xۇ,ItA_A7W1EF=<@2NRGͶ+q{/G/)WN)TOPNJP`v{Ny駃O}iIW ]Z'n86_qlKl,H\Al>Gx6ʅ MhnMp/W[U>I ~>`~]I%y'TJ7 `gl9AUf/\"KIncrKUomjIנL?qR.-RBE@ -pbXkʹʉ#RqrKi j;XTPDt .nj-]%?xm7v"FY6 9y)h19E6*Bu{'J[BWodYN-.V,F̙1vR{ntzhvlXM yw{N@9ܤjY`AT^: *݄!N1}Ek,ʫ4^({6G-,H(0" ]ŵpX RtɤK1KY$;e 9eg:ڣ ՞apH(рa;ppLC!K,oS:)bEh P$ :ָr*zԥ( %X *I$"=k+Y(Ƚ!?mjTp_ [LGH.ut-aTDr+nU^RDm.$N0] ^%'$װZgdzvm MrhMy={E)qXO?MWTg^C}{I @j)A`jՅGuyK0Pcdyҿ@Tw EI8y;T&вre^h*atE_8Xg_sI3*KƂsLhSQ[cZ!+V؟OILj跉UO;-׆#s&l#x 6LrVIxxz7[_oP[Bm qޜcbgS91!cGb(C|[ T-uΑ0P<2mB#n"Ώ aC5r$0'#ם10Y\D\^x^Fhz.b,�7^dAg) RKL"ZmǪ"EfEHY1Jfa8miS/>Ci%ut&&y`]H$EkXTSo4O@EϰfDJM8c-nD$rM:@mmL=t/uIJրqNL.P"EKrb(Z"*7$/3ҬU\Ώ_3fpyD!#2L`ޢ<6]:0LkN 0rb 8defoAXGRlWUl@Ϣ45]e=8ԁvHh:[ ȬG=S'io|tYC{l|,0?8up51aMC fHE=:bUxIdJ|\cwW%O<#=lK:/`h \}`s2o,R#ZUhH&S gNʰ /sIR (,o=%BܨpH| M9ukTT'[kE - kQ\A"jok^^s{"oE Qݲ\-ȆMx0ZĴִ3Яv](\Xd{,[z~ɴ{׀R\v(zs6bY7ʞT,Pm" uG( #I4+Sli:cэ bY3K݅K #}s#%ʃ9ҎP!:jSW^<8oBI'zswE Җ)Swf=w#RLAMr_?1EtihBhD|@up[&Q3F.Y38PU|JN-KQh 9რ>zevBgg]2!+}Έؓ4&_~:}JSANK>[ٖZCElh\@cTX ϔBeIy]O4AxNlm7 MG+y͓25g~q2w㻜&bS6,iSw i)*OJu,Ll=])R+迌ABF$2tU fzB ; `Ơeqyo:r5]D@5Sz2=%وgLkL/߲$흀8X(sړ_Ed%JQѩ4>=0S@IwеLNq戀(Z]mwC):2"IQWA&G3,01a*b-hTƈP+>`H%GA3_kbu!U[2(Bh:*-lA2ًxZ6P#5ڰdo�yLnB̿K2\INQ#~@e0t÷//f|r|& Idup~S(em9\)Ow c^+)HKGxOc`#bƝo(vg^h ,^5]JƗc!SlS[6ZBSI`z/?Gv9}U^b2aJ֘Ua)e0%nZv{(U@_}GDpJ%zr )žGA%Z44/jY\~*b}(0qQhvm]dTlwbq .Ox!;}PI2Ͻ*Z݌aLgxک` )UF,YNG< LPT1<[|q@eԨ#xLEIkߞ Q0:0,|e\D Wv$km&7%S}t"`:썪/˾bzwe}\E 7_AjV^_vnZz-텿H}1y[# 3Dט_]Z+w̖}V=鄵do0_BI 'i8D8Ty2-< >@Z 8z?ŵ$ A9gvTZ ^Qc铟3K-ָjЃ`X-"Yʒ)&QRʪ1ek.P=UwmSu4RR lyq jz͇Slv{{ؔ)i* u: .c**7OYo[RQ:fxH(UP hT.^ѻ[ ]^'E-*| ; paɍTj z\ W~%j8D~PױB+ b1w%stM3ٓ{W^;VL[h"oG'([e&Xm2FĚjVA2;+>ȗC`wsS4>4gBpD/e,$E9ub? .Sh&W~0Z3' Vu4>+tM35N k JԘYKg{*ǩ)jUbxK'dF&ѻhsBtnb݂0a~ę7RaԎY|̓."/wS14}QM>6Rw%rGfzXr2X޹bgXendstream endobj 16 0 obj 6452 endobj 19 0 obj <> stream x]rƵ+8IsR&%*vJIl_fMR"]EɢJg 54'@^ PKU({~>BU_:z7==ӷRE>;*q4Nhw?AWPeQ}UUSGcSZTMQ Ck)T?6vR8C5ݹ~,F5*; ?OE;,{ajwiM߫h޽ޟA ֭~_P 7(~kҶԫJ~P#|G~(ƶFjzSs^SuHY(p7uVe f8Vq3-Y[zu-Eiɺߏ*o0[:$&EYP6Ht+}-ga7BIz`[Z9Po/dأ:?A?]zV~еۢk{r Df$P9dmǯ/=/Ng ^󠴰) EwLLoVeh</"}b {fa}'pl*k-G2lT`gqM:qe%K9dX2Ps|Wl\(ٱ|9ArAՀ#˶P d4@/.㹵wmko[ Pl *To*a%,xBph:3Y"YH]P2ey{ 9WKa5p4huF8c3ʑڽgcPJ 6U="6"nw3xqU{.(÷ /M{U~OY}=П}sԎqێJS}qsGhU : 0[ḯMѩ:r Y~T8PHM F Ĉ?ECHLB,@jX ''epǼ~!1M$~gPTcэ^HidJ:&|8Sx ۠w D=ܔ(U / 2b;y,+][R}匃xGH*91 po1FNhHH)~vU*,-rPNMޥqA0 C2z(vs%n,ZGvI]!zO-Ƕz:ˎ5P/ReL`qN@/j^kb "bF@ /973ĚLf *KVKI}]/Ș=[a[ 3ʩnd4+Dӷ}f245eѾV(I?`%A*17]{3!FPd&*1DO=˧RF؅aL.W ΁7ބxLvнXet<~C}}K= Cӏ F٣gִH]? usd.ʍv%̌y]]Q @R^s PeRnT'WloR[mK(Dywm_7!~_ݙر_XDiQ)DNR#*+Coa",uSAtn"u0U憻.HAY qH(t,-!]lDa5m] BM:#Ty4f ][4e;`Y\A3O^!"a]JhB+@)Kf\*eTxY1э#]kZۦRqH1kV;G4J3_$]V 9$}*6T=L[ޮlV(MwIA g*1̙(<)Fa?@4FaZ`K$6>GC * O=/PzD~gin[.y~p>@-P.OT5pj<9뱗Gg]I\oKd̲RD "s1^lFfTa۸NFyUܖ QK`P߫I;]"\3E7Nklyb !q&P؆wЫra䆸zI3PM/ir[[▵ ޤ#v!H٨|L23h8`8NR]}5 n'k[ex}<aƉC"$T;Uxs 7Pn@JL rPc]?h0$S }Z|R E۰K EAy#PVHlww?c s&+GCFPie1Ye >GwqZͦ t<f;Xw+ߘĽP[qa.l +1`[>GGB) i]qT--:3-Gb3<0suIN-ZK!Լ+Ŝb^ #a]hln,Uuzլ H|ɘB]yȹhYfNxrg̣z5Eu%,f2e#WqֹilȼXgEɱ&O:'G@Tw>5l>G)`ര2H":(|FDs| -1iLfLj23G @B [4IcmG GHr+5T1;!sN(9E~ϬJ{}r\$R'(Lc$$(F$nBp05#;##2ZNqh!ɞm(yƨـ'jOU(1zwCn Ӕf`p,$bҽYX&i.5$E[^j"DaK@vN/w 0鞀27 7s̡uZHd}џn弘n,(a+#$M%0gm`o&8M+Xpd8߬2XLQ^7VK3oPkLrbI;cUoe;4T8d5B:ΗlC/֝Cr*٣,`7ͰaAUMTc e nٛt 4Jx]%[Xd"PVtA5-j}aihiAif˧y4^Șz]OaF|5ǶQÍAN#:s_)1#H(T|$Zx=cSpO͘ YP4IPLq)PX| ="5"~|JļA"+KpOF6> 1.g:]JEUVkdq~~Z:_lj WвW议# wW}?=AG0) ^d\$''z\d w\B-XXC=$v*Axck9qAG+?wsSsSDx#ڜĔ,TmX`c2*R};҄4ujΑ<`љgSq>TSFV$[AR " -M!^j]}DGW0q萿teu8]wEG5RK" 3F@-kpr4j-[36#5,abk}ٌo?FW1]D[i 6or36m]tgU8 ҼUcT)ZAπ஥Ib4ms}6H 7L>wctott ]WRl.%!vej%ȑI8RDM;/qd#░ 6r>8le`{ƃfƟOȉw觉6]YOHl>fI /rOqvJ<$XdB5]Ye""˷/JKRwZm%N/G-:%Lʥ4bF& .` ECͺF1MZykDQ>RvnΩI'^O'Z<.(D6>\֖o\is;ReEEM,!='"1H\0eSVo:835:H}H-L5<ծgӄTgk[g=uOay_J! X0/:v{U "upq6R;$IWP+sPߐxÄFtAPtA;<3K ^ :QM1:q5xƨ- oqn[qXl /aD94endstream endobj 20 0 obj 6142 endobj 23 0 obj <> stream x[rS%;f0n4$vM.UI("*9<yOBvekmݔBzqWݽ->Md t&r*pkJ%,4݂NJktն&.O/YKs2ܙS/lv&P"\O8Z7j1DFa$;fsҝ .hn؏00l FЗ7\$ ̑\LýAO@T6B}ؼ&ktϜ7{~(,ʈM6 )a,@8D_W79N7ԇFϓ;y7 1(!m&C ]g  I󄒯E96B4:ԳNAL-Cn=ہgiR9Ӝ>7"YLVՂ-3[\SftCu#;H0tbȃ&޲ ׁTla$7y.xeg)8{f1q8} hFoSx-c@|B&%%xK/6)ƱLa-wgߩ7U3QiډhlLa Y4BCX9o-*_xOO_jS4/$i.v=i5.ń ȑ-lG(.`p1(\�Y׎*r# gYF,`X ]p(}6j6Mr=1v 86!24 |avBPr 3"+1<(Ʌ`6-KMN,ǗZbNbR aJq0؀ų՚V4OM|iNbtȳ*_HhAKNbtU1:Mdl# f-V`s z<3Z0?I`Wl`AoS'YDz5t&Udn2+eH8ԧtứ4PvfT'*fxuɎU~fK9%>A،܈?is /̯QN}nʘ7WuBy^'x ;*Z4" UMBԨ_#wutn{V8'zQjPK-+2K{˩4e8^`gY7QI|QrK)UZ h00Y6G|/|+Ui�s,#[ŝ=PhS&?Pkv9PsG2=Ĥ4U 3tWI6pTE#!r."oNrԊx+ .n v#hivw4ꄊ:5o__ep@}!* s}uOA )ITLfGHGKφ>(mhP7R&OlSg?m>m L""ϯ$~(?&F%4{LK/aT]CН&ٚhra)T(W{`աT6Ȓ( :*L+~%Q!F"K#=RۏQ޽cB]ο|,C<3ۅ5#~GlLc{eEAz[&3US ~O\ت`y䯽uϏN0GBidG&+i="5"yi:US3{bsrݗ=%T֎y?Ɩٽ[ @O+,Us,YDfQ} C' 1&7GHV!;&Ӫ'~ӄncSRlӥ{P R3%JMx>b; NJfʐ+6}ؠ!Vb<+IS>0L3>3gz(ͼ'3c;@+$p1ɘw^ݲ(t'iZ=C`k$JmtWL> l@0MCu$D]A #ԭޒNG'g9ؾYYf#ke:lF9"䝬)RQe&erv.gLo 3M|s2k0:6E@K;4B"FlnVEJq⿟,j * _Zh="3"7KdӛVսO ٻ,?e1.80 endstream endobj 24 0 obj 3038 endobj 4 0 obj <> /Contents 5 0 R >> endobj 14 0 obj <> /Contents 15 0 R >> endobj 18 0 obj <> /Contents 19 0 R >> endobj 22 0 obj <> /Contents 23 0 R >> endobj 3 0 obj << /Type /Pages /Kids [ 4 0 R 14 0 R 18 0 R 22 0 R ] /Count 4 /Rotate 0>> endobj 1 0 obj <> endobj 13 0 obj <> endobj 17 0 obj <> endobj 21 0 obj <> endobj 25 0 obj <> endobj 10 0 obj <> endobj 8 0 obj <> endobj 12 0 obj <> endobj 27 0 obj <> endobj 7 0 obj <> endobj 28 0 obj <> endobj 9 0 obj <> endobj 29 0 obj <> endobj 11 0 obj <> endobj 26 0 obj <>stream xX}xչϙl>&$& ,%5 IV $R& f1'[/7乂'iVf7\Dmb{>ګԫZ 1OKg6PrK9;;y{ Aڢ0ܧ1es0hȲm}߭B捡͡% hkoLgl_{kpKU v̰?Hfy훻{fy-D;k6 %᪐?}ͭS]ɡήDaCCxU( r ;7dYIdNx2a9 Ư!rq\b y݋| ' cg g!<~wzx0Ёkslnxِp8@!8 OcgA4Gq#d!qfZA6@.4~dt.Ѝ1ȇ(6Oq8b En(x.hp6X╦{7d菌su dN8M.fti07F߅_;y_t>! #7Jp;! g>"5S~qhFOPnٶAI%%Ed= #? p"gz!}_h8A6+f΃12EPK jkш߃uZ<řoFIU?=qbi(q]H$d㼗zr?FdG`,MONbz!`dEIUFMrRn{>_?%>(r9Q.(\BwF0./Y\zۢ%7TX7~-oAup/ooyuk4Ukw$0SD+5{!9LMworhv8a),燀+> R:K;/U˛G b8+_ -xcBıфx?L25rtV&.)GNowb5&&$r4lJ?",:i{z!mmf;09q2&Jx8fC= ߡ b웤YB /3ƆWm-^n═*,< ~<ۅ $mr$R'Bm$ Xk{qFm;zRl?+Ms0Dsv`-&o/O<k3,ȿMxV!Aqnq`8O+) l)WK6)Kʔ )UJ$)I%*'LKīY?U$y:]P+o]]/M^ߖo| @Gn;z>`Wk[՜OEy2o-hSqyk}sz s^VY! ]#d~<qb @&aV O(A@(IV&x ym@W7=z;ܮh[I&ggj%|+■hCɚ>)3=+>jZGqĬ+nGH ԛՓ2gB:BB8q7# X8qxbZ[ÎNz┐Z+O Cf@u"z߶v۬(ѾSϼ@sK;+iե.%8tS7( |!kjnyxX\sua:X͇>lllf7VJP\(iJ2鯰YC̭tӾ19)xK4S3j{RwtcS*+3p/O}zjjgytdkwSww#tnTw_* mJ0WukSDa`NXm|BF"^R`iuu%%bw/{Iӛ1M0 ,}хOQ[QhSKH83k'. Ifʕ24I endstream endobj 2 0 obj <>endobj xref 0 30 0000000000 65535 f 0000021942 00000 n 0000027009 00000 n 0000021853 00000 n 0000021279 00000 n 0000000015 00000 n 000

05.3 Dati preclinici di sicurezza - [Vedi Indice].

8 00000 n 0000022577 00000 n 0000022264 00000 n 0000022751 00000 n 0000022199 00000 n 0000023024 00000 n 0000022326 00000 n 0000021990 00000 n 0000021421 00000 n 0000005368 00000 n 0000011892 00000 n 000002

06.0 INFORMAZIONI FARMACEUTICHE - [Vedi Indice].

06.1 Eccipienti - [Vedi Indice].

000 n 0000022577 00000 n 0000022264 00000 n 0000022751 00000 n 0000022199 00000 n 0000023024 00000 n 0000022326 00000 n 0000021990 00000 n 0000021421 00000 n 0000005368 00000 n 0000011892 00000 n 000002

06.2 IncompatibilitÓ - [Vedi Indice].

n 0000022577 00000 n 0000022264 00000 n 0000022751 00000 n 0000022199 00000 n 0000023024 00000 n 0000022326 00000 n 0000021990 00000 n 0000021421 00000 n 0000005368 00000 n 0000011892 00000 n 000002

06.3 Periodo di validitÓ - [Vedi Indice].

00022577 00000 n 0000022264 00000 n 0000022751 00000 n 0000022199 00000 n 0000023024 00000 n 0000022326 00000 n 0000021990 00000 n 0000021421 00000 n 0000005368 00000 n 0000011892 00000 n 000002

06.4 Speciali precauzioni per la conservazione - [Vedi Indice].

2577 00000 n 0000022264 00000 n 0000022751 00000 n 0000022199 00000 n 0000023024 00000 n 0000022326 00000 n 0000021990 00000 n 0000021421 00000 n 0000005368 00000 n 0000011892 00000 n 000002

06.5 Natura e contenuto della confezione - [Vedi Indice].

00000 n 0000022264 00000 n 0000022751 00000 n 0000022199 00000 n 0000023024 00000 n 0000022326 00000 n 0000021990 00000 n 0000021421 00000 n 0000005368 00000 n 0000011892 00000 n 000002

06.6 Istruzioni per l'uso e la manipolazione - [Vedi Indice].

00 n 0000022264 00000 n 0000022751 00000 n 0000022199 00000 n 0000023024 00000 n 0000022326 00000 n 0000021990 00000 n 0000021421 00000 n 0000005368 00000 n 0000011892 00000 n 000002

07.0 TITOLARE DELL'AUTORIZZAZIONE ALL'IMMISSIONE IN COMMERCIO - [Vedi Indice].

0000022264 00000 n 0000022751 00000 n 0000022199 00000 n 0000023024 00000 n 0000022326 00000 n 0000021990 00000 n 0000021421 00000 n 0000005368 00000 n 0000011892 00000 n 000002

08.0 NUMERI DELLE AUTORIZZAZIONI ALL'IMMISSIONE IN COMMERCIO - [Vedi Indice].

0022264 00000 n 0000022751 00000 n 0000022199 00000 n 0000023024 00000 n 0000022326 00000 n 0000021990 00000 n 0000021421 00000 n 0000005368 00000 n 0000011892 00000 n 000002

09.0 DATA DELLA PRIMA AUTORIZZAZIONE/RINNOVO DELL'AUTORIZZAZIONE - [Vedi Indice].

264 00000 n 0000022751 00000 n 0000022199 00000 n 0000023024 00000 n 0000022326 00000 n 0000021990 00000 n 0000021421 00000 n 0000005368 00000 n 0000011892 00000 n 000002

10.0 DATA DI REVISIONE DEL TESTO - [Vedi Indice].

00000 n 0000022751 00000 n 0000022199 00000 n 0000023024 00000 n 0000022326 00000 n 0000021990 00000 n 0000021421 00000 n 0000005368 00000 n 0000011892 00000 n 0000022060 00000 n 0000021565 00000 n 0000011913 00000 n 0000018127 00000 n 0000022110 00000 n 0000021709 00000 n 0000018148 00000 n 0000021258 00000 n 0000022160 00000 n 0000023224 00000 n 0000022484 00000 n 0000022658 00000 n 0000022833 00000 n trailer << /Size 30 /Root 1 0 R /Info 2 0 R /ID [<3EF6BEF49F0A64545D0EBF72AA63CF6F><3EF6BEF49F0A64545D0EBF72AA63CF6F>] >> startxref 27231 %%EOF

 

home

 


Ultimo aggiornamento: 15/12/2012
carloanibaldi.com - Copyright ę 2000-2012 - Anibaldi.it@Network - Tutti i diritti riservati.
[http://www.carloanibaldi.com/terapia/schede/summary.htm]